ConferenceJournal of Clinical Oncology · January 1, 2024
Background: The human cytomegalovirus (CMV) antigen pp65 is ubiquitously expressed in high-grade glioma (HGG) and medulloblastoma but not in adjacent brain. The primary objective of this first-in-human phase I trial (NCT03299309) was to assess the safety a ...
Full textCite
ConferenceJournal of Clinical Oncology · June 1, 2023
9128 Background: GT103 is a first-in-class IgG3 monoclonal antibody that was derived from a single human B cell and inhibits complement factor H (CFH). CFH is implicated in cancer immune evasion and overexpression portends a poor ...
Full textCite
ConferenceBreast Cancer Res Treat · January 2023
PURPOSE: Current systemic therapy guidelines for patients with HER2 + breast cancer brain metastases (BCBrM) diverge based on the status of extracranial disease (ECD). An in-depth understanding of the impact of ECD on outcomes in HER2 + BCBrM has never bee ...
Full textLink to itemCite
ConferenceJournal of Clinical Oncology · May 20, 2021
e14002 Background: It is estimated that 30% of patients with metastatic human epidermal growth factor receptor 2-positive (HER2+) breast cancer will develop brain metastases. Current standard of care options for HER2+ breast canc ...
Full textCite
ConferenceJournal of Clinical Oncology · May 20, 2021
1041 Background: BCBMs are very common in metastatic HER2+ breast cancer. CNS-directed local therapy is the gold standard for treatment, followed by systemic HER2-targeted therapies. In patients with HER2+ BCBM and stable extracr ...
Full textCite
ConferenceJournal of Clinical Oncology · May 20, 2019
e13526 Background: Recurrence of high-grade glioma (HGG) (WHO grade III-IV) is a nearly universal phenomenon and necessitates the development of new therapeutic modalities. Two possible immunotherapeutic modalities are checkpoint ...
Full textCite
ConferenceJournal of Clinical Oncology · May 20, 2019
541 Background: Breast cancer therapy causes marked impairments in CV function predisposing to elevated risk of CV morbidity. We investigated the effects of two AT dosing regimens on CV function in post-treatment patients with op ...
Full textCite
ConferenceJournal of Clinical Oncology · May 20, 2019
2060
Background: We completed a study evaluating a single intratumoral delivery of PVSRIPO in recurrent WHO grade IV MG patients (N Engl J Med. 2018 Jul 12;379(2):150-161). Some patients who originally benefitted from the infusion of PVSRIPO demonstrated ...
Full textLink to itemCite
ConferenceNeuro-Oncology · November 1, 2017
RATE-36
INTRODUCTION
Primary central nervous system lymphoma (PCNSL) is a subtype of non-Hodgkin’s lymphoma that involves the brain, spinal cord or leptomeninges, without evidence of systemic disease. This rare disease accounts for ~3% of all primary centr ...
Full textLink to itemCite
ConferenceJournal of Clinical Oncology · May 20, 2017
e13533 Background: The live attenuated oral poliovirus vaccine was modified to contain a heterologous internal ribosomal entry site stemming from human rhinovirus type 2, creating PVSRIPO. PVSRIPO recognizes CD155, an oncofetal c ...
Full textLink to itemCite
ConferenceJournal of Clinical Oncology · May 20, 2017
e13532 Background: D2C7 immunotoxin (D2C7-IT) is a dual-specific recombinant immunotoxin consisting of EGFR-wt and EGFRvIII monoclonal antibodies with a genetically engineered Pseudomonas exotoxin, PE-38KDEL. The primary objectiv ...
Full textLink to itemCite
ConferenceJournal of Clinical Oncology · May 20, 2017
e21636 Background: At diagnosis, GBM patients face the immediate challenge of significant morbidity and mortality. In this population, we have shown that better exercise behavior is an independent prognostic factor for improved s ...
Full textLink to itemCite
ConferenceNeurology · April 27, 2017
Objective: To evaluate the feasibility and safety of administering brain tumor stem cell (BTSC) mRNA-loaded dendritic cells (DC) to patients with recurrent GBM.
Background: BTSC CD133+ contribute to GBM propagation and are associated with chemo-radiation ...
Link to itemCite
ConferenceSupport Care Cancer · October 2016
BACKGROUND: In malignant glioma (MG) patients undergoing radiation therapy (RT) with concomitant temozolomide, chemoradiation-induced nausea and vomiting (cRINV) degrades quality of life (QoL) and reduces treatment adherence, which thereby potentially comp ...
Full textLink to itemCite
ConferenceJournal of Clinical Oncology · May 20, 2016
Background: The live attenuated oral (SABIN) serotype 1 poliovirus vaccine was modified to contain a heterologous internal ribosomal entry site stemming from human rhinovirus type 2, creating PVSRIPO. PVSRIPO recognizes CD155, an oncofetal cell adhesion mo ...
Full textLink to itemCite
ConferenceJournal of Clinical Oncology · May 20, 2016
ackground: The inherent biologic specificity of immunotherapy offers the prospect of targeting neoplastic cells more precisely. Dendritic cells (DCs) are endowed with an extraordinary ability to activate CD4+ and CD8+ T-cells, and DCs loaded with antigens ...
Full textLink to itemCite
ConferenceJournal of Clinical Oncology · May 20, 2016
Background: Overall survival of patients with glioblastoma (GBM) remains dismal with range from 12-14 months. In addition to the oncologic burden that these patients face during the disease trajectory, there are demonstrable neurologic and cognitive challe ...
Full textLink to itemCite
